BioCentury
ARTICLE | Clinical News

Tivopath tivozanib regulatory update

December 3, 2012 8:00 AM UTC

Aveo and partner Astellas said FDA accepted for review an NDA for Tivopath tivozanib to treat renal cell carcinoma (RCC). FDA did not grant Aveo's request for 6-month Priority Review and assigned the ...